Headlines

(Image: Getty/Robert Daly)

UCB set to buy Ra Pharma for $2.1bn

With both boards of directors in agreement, UCB is on track to add the clinical stage biopharma company and its lead drug candidate, zilucoplan, to its portfolio.

Global Industry News

Hot Topics

Spotlight

Follow us

Products

View more

Featured Suppliers

All suppliers